What are the implications of the Keto-CTA (Ketoconazole-Computed Tomography Angiography) study results?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clarification Needed: No "Keto-CTA" Study Exists

I cannot find any study called "Keto-CTA" (Ketoconazole-Computed Tomography Angiography) in the medical literature provided or in established medical research. This appears to be either a misnamed study or a conflation of unrelated medical terms.

Possible Interpretations

If You Mean CTA (CT Angiography) Studies:

The evidence provided discusses CTA performance characteristics across multiple clinical scenarios, but none involve ketoconazole:

For Lower Gastrointestinal Bleeding:

  • CTA demonstrates 90% sensitivity and 92% specificity for detecting lower GI bleeding, with ability to identify bleeding rates as slow as 0.3 mL/min 1
  • CTA identified active bleeding or potential bleeding lesions in 92% of cases versus only 29% identified by transcatheter arteriography 1
  • Negative CTA in hemodynamically stable patients indicates conservative management can be safely initiated, with approximately 75% settling spontaneously 1

For Acute Mesenteric Ischemia:

  • CTA should be performed without delay in any patient with suspected acute mesenteric ischemia, as every 6 hours of diagnostic delay doubles mortality 1
  • Sensitivity ranges from 93-100% with specificity of 97.9-100% for detecting mesenteric ischemia 1

For Giant Cell Arteritis:

  • CTA shows 67-73% sensitivity and 85-98% specificity for GCA diagnosis, though it is not recommended as first-line imaging 2
  • CTA demonstrates high concordance with FDG-PET/CT (kappa: 0.64-1) for detecting GCA 1, 2

If You Mean Ketoconazole Studies:

The evidence discusses ketoconazole's safety profile and hepatotoxicity risk, but these are completely unrelated to CTA imaging:

  • In drug interaction studies with 2,355 participants, only 1.7% had elevated liver transaminases with no deaths reported 3
  • When used as antifungal treatment (median 276 days), 5.6% of patients developed elevated liver enzymes 3
  • Symptomatic hepatic injury occurs in approximately 1 in 15,000 exposed individuals 4

Request for Clarification

Please provide the correct study name or clarify what specific clinical question you are asking about. The term "Keto-CTA" does not exist in medical literature as a recognized study or diagnostic modality.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Imaging Modalities for Giant Cell Arteritis Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.